Vancomycin Way of Administration: Where is the Evidence? | Zendy

Maria Adriana Cataldo | Zendy; Evelina Tacconelli | Zendy; Federico Pea | Zendy; Nicola Petrosillo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vancomycin Way of Administration: Where is the Evidence?

Author(s) -

Maria Adriana Cataldo,

Evelina Tacconelli,

Federico Pea,

Nicola Petrosillo

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir343

Subject(s) - medicine , vancomycin , administration (probate law) , intensive care medicine , medline , staphylococcus aureus , bacteria , biology , political science , law , genetics

To the Editor—Vancomycin way of administration in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections is a controversial issue. In daily practice, many clinicians prefer to use continuous infusion (CoI) instead of intermittent infusion (InI), mainly in severe patients admitted in intensive care units (ICUs). Recently published Infectious Diseases Society of America (IDSA) guidelines for the treatment of MRSA infections do not clarify the issue and state that ‘‘because of the lack of a clear benefit over intermittent dosing, and because

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research